Video Experimental Relacionado
Updated: Jun 23, 2026
10:33
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Estructura del dominio catalítico de la fosfodiesterasa 5 humana con moléculas de fármaco unidas
Byung-Je Sung1, Kwang Yeon Hwang, Young Ho Jeon
1Division of Drug Discovery, CrystalGenomics, Inc., Daedeok Biocommunity, Jeonmin-dong, Yuseong-gu, Daejeon, 305-390, South Korea.
Nature
|September 5, 2003
Resumen
Los investigadores han determinado las estructuras 3D de la enzima PDE5, un objetivo clave para los medicamentos para la disfunción eréctil. Estas estructuras, complejas con sildenafil, tadalafil y vardenafil, ayudarán a desarrollar inhibidores de la PDE más efectivos.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Biología Estructural Biología estructural.
- Farmacología Farmacología.
Sus antecedentes:
- Las fosfodiesterasas (PDEs) regulan la señalización de nucleótidos cíclicos y son objetivos farmacológicos cruciales para diversas enfermedades.
- La PDE5 específica del cGMP es la enzima principal responsable de la hidrólisis del cGMP en el cuerpo cavernoso humano.
- Las estrategias terapéuticas actuales para la disfunción eréctil utilizan inhibidores de la PDE, pero las estructuras selectivas de la PDE son limitadas.
Objetivo del estudio:
- Para presentar las estructuras tridimensionales del dominio catalítico PDE5 humano.
- Para visualizar el complejo de PDE5 con tres moléculas de fármacos conocidos: sildenafil, tadalafil y vardenafil.
Principales métodos:
- Se empleó cristalografía de rayos X para determinar las estructuras.
- El dominio catalítico de la PDE5 humana (residuos 537-860) fue cristalizado en complejo con sildenafil, tadalafil y vardenafil.
Principales resultados:
- El estudio presenta las primeras estructuras 3D reportadas de PDE5 humano en complejo con sildenafil, tadalafil y vardenafil.
- Estas estructuras revelan las interacciones de unión de estos fármacos dentro del dominio catalítico PDE5.
Conclusiones:
- Las estructuras del complejo de fármacos PDE5 determinadas proporcionan información valiosa para el diseño racional de inhibidores novedosos, potentes y selectivos de la PDE.
- Estos hallazgos pueden acelerar el desarrollo de terapias mejoradas con perfiles farmacológicos mejorados para afecciones como la disfunción eréctil.
Videos de Conceptos Relacionados
01:01Phosphodiester Linkages
Overview
Phosphodiester bond forms when a phosphoric acid molecule (H3PO4) links with two hydroxyl groups (–OH) of two other molecules, forming two ester bonds. Two water molecules are released in this process. The phosphodiester bond is commonly found in nucleic acids (DNA and RNA) and plays a critical role in their structure and function.
Phosphodiester Bonds Link Nucleotides Together
DNA and RNA are polynucleotides or long chains of nucleotides that are linked together. A nucleotide is...
Phosphodiester bond forms when a phosphoric acid molecule (H3PO4) links with two hydroxyl groups (–OH) of two other molecules, forming two ester bonds. Two water molecules are released in this process. The phosphodiester bond is commonly found in nucleic acids (DNA and RNA) and plays a critical role in their structure and function.
Phosphodiester Bonds Link Nucleotides Together
DNA and RNA are polynucleotides or long chains of nucleotides that are linked together. A nucleotide is...
02:34Enzymes
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
02:54Protein Kinases and Phosphatases
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
01:18ATP Synthase: Structure
ATP synthase or ATPase is among the most conserved proteins found in bacteria, mammals, and plants. This enzyme can catalyze a forward reaction in response to the electrochemical gradient, producing ATP from ADP and inorganic phosphate. ATP synthase can also work in a reverse direction by hydrolyzing ATP and generating an electrochemical gradient. Different forms of ATP synthases have evolved special features to meet the specific demands of the cell. Based on their specific feature, ATP...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...